Searched for
VORICONAZOLE
Glenmark, Sun Pharma, Zydus recall products in USGlenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the ...- Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...
- Medicine for bearish markets: 5 Indian pharma stocks with upside potential of up to 32%There are some sectors which are able to face bears in a better way. The reason, the operating matrix of those sectors is such that rising ...
- Second & better attempt; 5 Indian pharma stocks with upside potential of up to 31%Both, in terms of bottomline and stock price performance, pharma stocks had been under pressure for a long time. Partly this under performa...
- After a long winter finally some tailwinds; 6 pharma stocks with upside potential of up to 31%While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...
- A Healthy Dose! 4 midcap pharma stocks with upside potential of up to 36%After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...
- Finally out of the woods? 4 midcap pharma stocks with an upside potential up to 34 %Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...
- On a path to recovery: 5 midcap pharma stocks with an upside potential up to 32%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized In...
- On a path to recovery; 5 mid-cap pharma stocks with an upside potential up to 41%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in bearish markets. Some of them are mid-sized Ind...
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...
- Centre issues advisory on management of Mucormycosis fungal infection in COVID-19 patientsWarning symptoms include pain and redness around eyes and nose, fever, headache, coughing, shortness of breath, bloody vomits and altered m...
- Zydus Cadila gets USFDA nod to market 4 generic productsPharma firm Zydus Cadila today said it has received final approvals from the US health regulator to market four generic products in America.
- Lupin launches voriconazole tabletsThe medicines are indicated for use in patients 12 years of age and older in the treatment of fungal infections, including invasive Aspergi...
- Lupin gets USFDA nod for fungal infection drugThe company's products are generic versions of PF Prism C.V's Vfend tablets and Vfend oral suspension in the same strengths, report added.
- Lupin gets USFDA's final nod for fungal treatment drugLupin has received final approval from the US health regulator to market Voriconazole tablets, used for the treatment of fungal infections,...
- Sensex surges 575 points, Nifty50 holds above 7,900 levelThere was hectic buying on Dalal Street, as investors turned bullish after Morgan Stanley upgraded the Indian market to ‘overweight’ from ‘...
- Zydus Cadila gets USFDA's final nod for fungal treatment drugShares of Cadila Healthcare, the group's listed entity, were trading 0.41 per cent up at Rs 319.45 on BSE in the afternoon session.
- Aurobindo Pharma gets USFDA nod for fungal infections tablets"The approved product has an estimated market size of $103 million for the twelve months ending November 2015 according to IMS," the compan...
- Glenmark gets USFDA nod for fungal infections treatment drugGlenmark Pharmaceuticals said it has received final approval from the US health regulator for Voriconazole Tablets, used to treat fungal in...
- Local pharma strikes first in patent warGlobal innovator pharma companies and domestic generic players are sparring with each other in the wake of India’s new product patent regim...
Load More
